Sertraline in Adults With Pervasive Developmental Disorders: A Prospective Open-Label Investigation
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
The short-term efficacy and tolerability of sertraline for adults with pervasive developmental disorders (PDDs) were assessed in this investigation. Forty-two adults with PDDs (autistic disorder, N = 22; Asperger's disorder, N = 6; and PDD not otherwise specified [NOS], N = 14) participated in a 12-week, open-label, systematic trial of sertraline. Behavioral ratings of repetitive symptoms, aggression, and social relatedness were obtained at baseline and after 4, 8, and 12 weeks of sertraline administration. Twenty-four (57%) of 42 patients showed significant improvement, primarily in repetitive and aggressive symptoms. Statistically significant changes in measures of social relatedness did not occur. Patients with autistic disorder and PDD NOS did significantly better than those with Asperger's disorder. Based on global improvement item criteria from the Clinical Global Impression Scale, 15 of 22 (68%) patients with autistic disorder, none of six (0%) patients with Asperger's disorder, and 9 of 14 (64%) patients with PDD NOS were categorized as treatment responders. Sertraline was well tolerated; no adverse cardiovascular effects, extrapyramidal symptoms, or seizures were identified. These findings suggested that sertraline may be an effective treatment for interfering repetitive and aggressive symptoms in adults with PDDs. Definitive statements about the efficacy and tolerability of sertraline for treating adults with PDDs must await results from double-blind, placebo-controlled trials. These preliminary results should not be generalized to include children and adolescents with PDDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
The Yale-Brown Obsessive Compulsive Scale: II. Validity
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110054008 · Cited by 2,799
Lord, C., Rutter, M., Goode, S., Heemsbergen, J., Jordan, H., Mawhood, L., & Schopler, E. (1989) · Journal of Autism and Developmental Disorders · doi:10.1007/bf02211841 · Cited by 2,030
Effects of tryptophan depletion in drug-free adults with autistic disorder
McDougle, C. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110029004 · Cited by 301
Self-citation
Cited by
Autism Spectrum Disorder: Classification, diagnosis and therapy
Sharma, S. R., Gonda, X., & Tarazi, F. I. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.007 · Cited by 673
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Brignell, A., Randall, M., Silove, N., & Hazell, P. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub3 · Cited by 415
Current Enlightenment About Etiology and Pharmacological Treatment of Autism Spectrum Disorder
Eissa, N., Al-Houqani, M., Sadeq, A., Ojha, S. K., Sasse, A., & Sadek, B. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00304 · Cited by 260
Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD)
Williams, K., Wheeler, D. M., Silove, N., & Hazell, P. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004677.pub2 · Cited by 131
Medications for Adolescents and Young Adults With Autism Spectrum Disorders: A Systematic Review
Dove, D., Warren, Z., McPheeters, M. L., Taylor, J. L., Sathe, N. A., & Veenstra-VanderWeele, J. (2012) · Pediatrics · doi:10.1542/peds.2012-0683 · Cited by 115
Metadata
- Authors
- McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1998-02
- Volume
- 18
- Issue
- 1
- Pages
- 62-66
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2319216822
- Cited by
- 132
- References
- 4
- FWCI
- 4.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sertraline in Adults With Pervasive Developmental Disorders: A Prospective Open-Label Investigation. https://app.cochat.ai/papers/10.1097/00004714-199802000-00010
- The paper
- McDougle, C. J., Brodkin, E. S., Naylor, S. T., Carlson, D. C., Cohen, D. J., & Price, L. H. (1998). Sertraline in Adults With Pervasive Developmental Disorders: A Prospective Open-Label Investigation. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199802000-00010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.